GRN and frontotemporal dementia: As noted, AVB-101 and PR006 in the ASPIRE-FTD and PROCLAIM phase 1/2 gene replacement trials, respectively, have already received fast-track designation due to preliminary results showing efficacy in restoring progranulin levels [33,36].